BR112015022624A2 - regime de dose, e, método para tratamento de aterosclerose - Google Patents

regime de dose, e, método para tratamento de aterosclerose

Info

Publication number
BR112015022624A2
BR112015022624A2 BR112015022624A BR112015022624A BR112015022624A2 BR 112015022624 A2 BR112015022624 A2 BR 112015022624A2 BR 112015022624 A BR112015022624 A BR 112015022624A BR 112015022624 A BR112015022624 A BR 112015022624A BR 112015022624 A2 BR112015022624 A2 BR 112015022624A2
Authority
BR
Brazil
Prior art keywords
apo
treatment cycle
treating atherosclerosis
dose regimen
effective amount
Prior art date
Application number
BR112015022624A
Other languages
English (en)
Portuguese (pt)
Inventor
Goldberg Dennis
M Anantharamaiah G
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of BR112015022624A2 publication Critical patent/BR112015022624A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112015022624A 2013-03-14 2014-03-14 regime de dose, e, método para tratamento de aterosclerose BR112015022624A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782956P 2013-03-14 2013-03-14
US201361834992P 2013-06-14 2013-06-14
PCT/US2014/027719 WO2014152776A1 (en) 2013-03-14 2014-03-14 Apolipoprotein mimetics and uses thereof

Publications (1)

Publication Number Publication Date
BR112015022624A2 true BR112015022624A2 (pt) 2017-10-31

Family

ID=51581312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022624A BR112015022624A2 (pt) 2013-03-14 2014-03-14 regime de dose, e, método para tratamento de aterosclerose

Country Status (12)

Country Link
US (1) US20160002315A1 (enExample)
EP (1) EP2996706B1 (enExample)
JP (2) JP6570511B2 (enExample)
AU (2) AU2014239186B2 (enExample)
BR (1) BR112015022624A2 (enExample)
CA (1) CA2903869A1 (enExample)
DK (1) DK2996706T3 (enExample)
ES (1) ES2753381T3 (enExample)
IL (1) IL240787B (enExample)
MX (1) MX2015012818A (enExample)
NZ (1) NZ713291A (enExample)
WO (1) WO2014152776A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
WO2017120568A1 (en) * 2016-01-08 2017-07-13 Lipimetix Development, Inc. Apoe mimetic peptide compositions
HUE062709T2 (hu) * 2016-02-17 2023-11-28 Regeneron Pharma Módszerek az atherosclerosis kezelésére vagy megelõzésére ANGPTL3 inhibitor alkalmazásával
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
WO2023018876A2 (en) * 2021-08-11 2023-02-16 The Regents Of The University Of California Barrier function preserving peptides for membranes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US20130005645A1 (en) * 2010-01-06 2013-01-03 Vitek Michael P Apoe peptide dimers and uses thereof
BR112017001860A2 (pt) * 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal

Also Published As

Publication number Publication date
US20160002315A1 (en) 2016-01-07
IL240787A0 (en) 2015-10-29
JP6570511B2 (ja) 2019-09-04
JP2016515137A (ja) 2016-05-26
AU2017203911A1 (en) 2017-06-29
ES2753381T3 (es) 2020-04-08
JP2019089834A (ja) 2019-06-13
AU2014239186B2 (en) 2017-04-20
IL240787B (en) 2019-07-31
AU2014239186A1 (en) 2015-10-08
AU2017203911B2 (en) 2019-03-07
EP2996706B1 (en) 2019-07-31
EP2996706A1 (en) 2016-03-23
DK2996706T3 (da) 2019-10-21
JP6772317B2 (ja) 2020-10-21
MX2015012818A (es) 2016-05-12
EP2996706A4 (en) 2017-01-18
NZ713291A (en) 2017-04-28
CA2903869A1 (en) 2014-09-25
WO2014152776A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
MX384403B (es) Terapia de combinación para el tratamiento del cáncer.
BR112015022624A2 (pt) regime de dose, e, método para tratamento de aterosclerose
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
BR112016030944A8 (pt) método para administração de um agente ativo a um usuário
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
MX2016004316A (es) Inhalador de polvo seco.
JP2012046524A5 (enExample)
BR112018014850A2 (pt) dispositivo de injeção usável
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
BR112014011223A8 (pt) Método de tratar uma doença proliferativa
MX2016007370A (es) Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
MX385725B (es) Composición farmacéutica que comprende sumatriptán para tratamiento de migraña.
AR102903A1 (es) Inhalador de polvo seco
DOP2014000258A (es) Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro
BR112015030388A2 (pt) formulação farmacêutica
IL283422A (en) Methods of treating or preventing asthma by adding an IL-4R antagonist

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: UAB RESEARCH FOUNDATION (US) , LIPIMETIX DEVELOPME

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.